Fluid and pharmacological agents for adhesion prevention after gynaecological surgery

Growth factors in the regulation of reparative response in the presence of peritoneal damage

“…This observation calls indeed for long-term preventive strategies, with demonstrated target effect during at least two weeks after surgery. Our hypothesis is supported by the fact that gels and other biomaterials appear to be the most effective adhesion prevention agents for use during gynecological surgery [ 25 ]. Gel formulation guarantees a slow and long-lasting release of the active agents indeed into the peritoneal cavity and the intra-abdominal postoperative wounds.…”

Growth factors in the regulation of reparative response in the presence of peritoneal damage

“…This observation calls indeed for long-term preventive strategies, with demonstrated target effect during at least two weeks after surgery. Our hypothesis is supported by the fact that gels and other biomaterials appear to be the most effective adhesion prevention agents for use during gynecological surgery [ 25 ]. Gel formulation guarantees a slow and long-lasting release of the active agents indeed into the peritoneal cavity and the intra-abdominal postoperative wounds.…”

Non-clinical safety of novel cross-linked chondroitin sulfate (SI-449) as an anti-adhesion barrier for abdominal and pelvic surgeries

“…In the U.S., INTERGEL ® Adhesion Prevention Solution, a 0.5% ferric hyaluronate gel, was withdrawn from the market in 2003 due to concerns of adverse events. 32 Currently, in the U.S., the non-clinical safety of anti-adhesion barriers must meet the requirements of the U.S. Food and Drug Administration (FDA) guidances, in addition to those of ISO 10993 standards. 26,33,34 Therefore, we evaluated the non-clinical safety of SI-449 to confirm its potential use in abdominal and pelvic surgeries.…”

The Efficacy of Hyaluronic Acid in Reducing Pelvic Adhesions in Patients Undergoing Gynecologic Laparoscopic Surgery: A Meta‐Analysis of Randomized Clinical Trials

“…To the best of the author's knowledge, this is the first meta‐analysis performed on the results of the hyaluronic acid application in laparoscopic gynecological surgery that focused on pelvic adhesion. Previous meta‐analyses on adhesion formation in gynecological surgeries involved other anti‐adhesion materials [ 25 , 26 , 27 ] or patients with other routes of surgeries, including laparotomy [ 28 ] or hysteroscopic surgeries [ 11 , 29 , 30 ]. Since adhesion formation is considerably lower in laparoscopic surgery, we excluded [ 31 ] all laparotomies to avoid heterogeneity.…”

Growth factors in the regulation of reparative response in the presence of peritoneal damage

“…This observation calls indeed for long-term preventive strategies, with demonstrated target effect during at least two weeks after surgery. Our hypothesis is supported by the fact that gels and other biomaterials appear to be the most effective adhesion prevention agents for use during gynecological surgery [ 25 ]. Gel formulation guarantees a slow and long-lasting release of the active agents indeed into the peritoneal cavity and the intra-abdominal postoperative wounds.…”

Non-clinical safety of novel cross-linked chondroitin sulfate (SI-449) as an anti-adhesion barrier for abdominal and pelvic surgeries

“…In the U.S., INTERGEL ® Adhesion Prevention Solution, a 0.5% ferric hyaluronate gel, was withdrawn from the market in 2003 due to concerns of adverse events. 32 Currently, in the U.S., the non-clinical safety of anti-adhesion barriers must meet the requirements of the U.S. Food and Drug Administration (FDA) guidances, in addition to those of ISO 10993 standards. 26,33,34 Therefore, we evaluated the non-clinical safety of SI-449 to confirm its potential use in abdominal and pelvic surgeries.…”

The Efficacy of Hyaluronic Acid in Reducing Pelvic Adhesions in Patients Undergoing Gynecologic Laparoscopic Surgery: A Meta‐Analysis of Randomized Clinical Trials

“…To the best of the author's knowledge, this is the first meta‐analysis performed on the results of the hyaluronic acid application in laparoscopic gynecological surgery that focused on pelvic adhesion. Previous meta‐analyses on adhesion formation in gynecological surgeries involved other anti‐adhesion materials [ 25 , 26 , 27 ] or patients with other routes of surgeries, including laparotomy [ 28 ] or hysteroscopic surgeries [ 11 , 29 , 30 ]. Since adhesion formation is considerably lower in laparoscopic surgery, we excluded [ 31 ] all laparotomies to avoid heterogeneity.…”

Growth factors in the regulation of reparative response in the presence of peritoneal damage

“…This observation calls indeed for long-term preventive strategies, with demonstrated target effect during at least two weeks after surgery. Our hypothesis is supported by the fact that gels and other biomaterials appear to be the most effective adhesion prevention agents for use during gynecological surgery [ 25 ]. Gel formulation guarantees a slow and long-lasting release of the active agents indeed into the peritoneal cavity and the intra-abdominal postoperative wounds.…”

Non-clinical safety of novel cross-linked chondroitin sulfate (SI-449) as an anti-adhesion barrier for abdominal and pelvic surgeries

“…In the U.S., INTERGEL ® Adhesion Prevention Solution, a 0.5% ferric hyaluronate gel, was withdrawn from the market in 2003 due to concerns of adverse events. 32 Currently, in the U.S., the non-clinical safety of anti-adhesion barriers must meet the requirements of the U.S. Food and Drug Administration (FDA) guidances, in addition to those of ISO 10993 standards. 26,33,34 Therefore, we evaluated the non-clinical safety of SI-449 to confirm its potential use in abdominal and pelvic surgeries.…”

The Efficacy of Hyaluronic Acid in Reducing Pelvic Adhesions in Patients Undergoing Gynecologic Laparoscopic Surgery: A Meta‐Analysis of Randomized Clinical Trials

“…To the best of the author's knowledge, this is the first meta‐analysis performed on the results of the hyaluronic acid application in laparoscopic gynecological surgery that focused on pelvic adhesion. Previous meta‐analyses on adhesion formation in gynecological surgeries involved other anti‐adhesion materials [ 25 , 26 , 27 ] or patients with other routes of surgeries, including laparotomy [ 28 ] or hysteroscopic surgeries [ 11 , 29 , 30 ]. Since adhesion formation is considerably lower in laparoscopic surgery, we excluded [ 31 ] all laparotomies to avoid heterogeneity.…”